Antisense strategy: Biological utility and prospects in the treatment of hematological malignancies

Leukemia and Lymphoma

Volumn 24, Issue 3-4, 1997, Pages 267-281

  Warzocha, Krzysztof ^a,c   Wotowiec, Dariusz ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Antisense; Leukemia; Lymphoma; Oligonucleotides; Treatment

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; MESSENGER RNA; PROTEIN P53;

BONE MARROW PURGING; DRUG DELIVERY SYSTEM; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG STABILITY; DRUG UPTAKE; GENE EXPRESSION REGULATION; GENE FUSION; HUMAN; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 0031051195     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039014     Document Type: Review

References (101)

1. Nellen, W. and Lichtenstein, C. (1993) What makes an mRNA ami-sense-itive? Trends Biol. Sci., 18, 419-423.
2. Hélène, C. (1994) Control of oncogene expression by antisense nucleic acids. Eur. J. Cancer, 30A, 1721-1726.
3. Bock, L. C., Griffin, L. C., Latham, A., Vermaas, E. H. and Toole, J. J. (1992) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355, 564-566.
4. Fenster, S. D., Wagner, R. W., Froehler, B C. and Chin, D. J. (1994) Inhibition of human immunodeficiency virus type I-env expression by C-S oligonucleotides specific for Rev response element stem loop. J. Biochemistry, 33, 8391-8398.
5. Bacon, T. and Wickstrom, E. (1991) Daily addition of an anti-c-myc DNA oligomer induces granulocytic differentiation of human promyelocytic leukemia HL-60 cells in both serum-containing and serum-free media. Oncogene Res., 6, 21-32.
6. Daaka, Y. and Wickstrom, E. (1990) Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T-24-transformed NIH3T3 cells. Oncogene Res., 5, 267-275.
7. Chiang, M. Y., Chan, H., Zounes, M. A., Freier, S. M., Lima, W. F. and Bennet, C. F. (1991) Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem., 18162-18171.
8. Goodchild, J. (1989) Antisense inhibitors of gene expression. In Oligodeoxunucleotides, J. Cohen, Ed. (Macmillan, London), pp 53-77.
9. Becker, D., Meier, C. and Herlyn, M. (1989) Proliferation of malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against fibroblast growth factor. EMBO J., 8, 3685-3691.
10. Morrison, R. (1991) Suppression of basic fibroblast growth factor expression by antisense ohgodeoxynucleotides inhibits the growth of transformed human astrocytes. J. Biol. Chem., 728-733.
11. Rajagopal, P. and Feigon, J. (1989) NMR studies of triple-strand formation from the homopurine-homopryrimidine deoxyribonucleotides d(GA)h and d(TC)h. J. Biochemistry, 28, 7859-7870.
12. Radhakrishnan, I., Gao, X., de los Santos, C., Live, D. and Patel, D. J. (1991) NMR structural studies of intramolecular (Y+)n (R-t-)n (Y-)n DNA triplexes in solution: imino and amino proton and nitrogen markers of GTA base triple formation. J. Biochemistry, 30, 9022-9030.
13. Cooney, M., Czernuszewicz, G., Postal, E. H., Flint, J. and Hogan, M. E. (1989) Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science. 241, 456-159.
14. Bcal, P. A. and Dervan, P. B. (1991) Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation. Science, 251, 1360-1363.
15. Thuong, N. T. and Hélène, C (1993) Sequence-specific recognition and modification of double-helical DNA. Angew. Chem. Int. Eng., 32, 666-690.
16. Dervan, P. B. (1992) Reagents for the site-specific cleavage of megabase DNA. Nature, 359, 87-88.
17. Stobel, S A , Doucette-Stamm, L. A., Riba, L., Housman, D. E. and Dervan, P. B. (1991) Site-specific cleavage of human chromosome mediated by triple-helix formation. Science, 254, 1639-1642.
18. Pei, D., Corey, D. R. and Schultz, P G. (1990) Site-specific cleavage of duplex DNA by a semisynthetic nuclease via triple-helix formation. Proc. Natl. Acad. Sci. USA, 87, 9858-9862.
19. Strobel, S. A. and Dervan, P. B. (1991) Single-site enzymatic cleavage of yeast genomic DNA mediated by triple helix formation. Nature. 350, 172-174.
20. Rothenburg, M., Johnson, G., Laughlin, C., Green, I., Cradock, J., Sarver, N. and Cohen, J. S. (1989) Oligonucieotides as antisense inhibitors of gene expression: therapeutic implications. J. Natl. Cancer Inst., 81, 1539-1544.
21. Mukhopadhyay, T., Tainsky, M., Cavender, C. and Roth, J. A. (1991) Specific inhibition of K-ras expression and tumongenicity of lung cancer cells by antisense RNA Cancer Res., 51, 1744-1748.
22. Cameron, F. H. and Jennings, P. A. (1989) Specific gene suppression by engineered ribozymes in monkey cells. Proc. Natl Acad Sci. USA, 86, 9139-9143.
23. Walder, R. Y. and Walder, J. A. (1988) Role of RNase H in hybrid-arrested translation by antisense Oligonucieotides. Proc. Natl. Acad. Sci. USA, 85, 5011-5015.
24. Woolf, T. M., Melton, D. A. and Jennings, C G. B. (1992) Specificity of antisense Oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA. 89, 7305-7309.
25. Gao, W. Y., Han, F. S., Storm, C., Egan, W. and Cheng, Y. C. (1992) Phosphorothioate Oligonucleotides are inhibitors of human DNA polymerases and RNase H: implications for antisense technology. Mol. Pharmacol., 41, 223-229.
26. Cazenave, C., Stein, C A , Loreau, N , Thuong, N. T., Neckers, L. M., Subasinghe, C., Hélène, C., Cohen, J. S. and Tolmé, J. J. (1989) Comparitvie inhibition of rabbit globin mRNA translation by modified antisense oligodeoxunucleotides. Nucleic Acids Res , 17, 4255-4273.
27. Ellington, A. D. and Szostak, J. W. (1990) In vitro selection of RNA molecules that bind specific ligands. Nature. 346, 818-822.
28. Bock, L. C., Griffin, L. C., Latham, J. A., Vermaas, E. H. and Toole, J. J. (1992) Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature, 355, 564-566.
29. Yakubov, L., Khaled, Z., Zhang, L. M., Truneh, A., Vlassov, V. and Stein, C. A. (1993) Oligonucieotides interact with recombinant CD4 at multiple sites. J Biol. Chem., 268, 18818-18823.
30. Perez, J. R., Li, Y., Stein, C. A., Majumder, S., van Oorschot, A. and Narayanan, R. (1994) Sequence independent induction of Sp-1 transcription factor activity by phosphorothioate oligodeoxynucleotides Proc. Natl. Acad. Sci. USA, 91, 5957-5961
31. Yamamoto, S., Kataoka, T., Kuramoto, E., Yano, O and Tokunaga, T. (1992) Unique palindromic sequences in synthetic ohgonucleotides are required to induce IFN and augment IFN-mediated natural killer activity J. Immunol., 148, 4072-4076.
32. Rathbone, M. P., Middlemiss, P. J., Gusbers, J. W., Deforge, S., Costello, P and Del Maestro, R. F. (1992) Purine nucleosides and nucleotides stimulate proliferation of a wide range of cell types. In Vitro Cell der Biol. 28A, 529-536.
33. Kamano, H., Tanaka, T., Yamaji, Y., Ikeda, K., Hata, Y., Shiotani, T , Ishida, T., Takahara, I. and Iriao, S. (1992) E. coli gpt gene expression effects in K562 human leukemia cell proliferation and erythroid differentiation altered by mycophenolic acid. Biochem. Int., 26, 537-543.
34. Stein, C. A. and Cheng, Y C (1993) Antisense oligonucleotides as therapeutic agents-Is the bullet really magical? Science, 261, 1004-1012.
35. Carter, G. and Lemoine, N. R. (1993) Antisense technology for cancer therapy: does it make sense? Br. J. Cancer. 67, 869-876
36. Gao, W., Han, F., Storm, L., Egan, W. and Cheung, Y. (1992) Phosphorothioate oligonucleotides are inhibitors for human DNA polymerases and RNAse H: implications for antisense technology. Mot. Pharmacol., 41, 223-229.
37. Tidd, D. M. and Warenius, H. M. (1989) Partial protection of oncogene. anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylophosphonate groups. Br. J. Cancer. 60, 343-350.
38. Tidd, D. M. (1992) Methylphosphonodiester/phosphodiester chimeric oligodeoxynucleotides. Biochem. Soc. Trans., 20, 746-749.
39. Tidd, D. M. (1990) A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy. Anticancer Res., 10, 1169-1182.
40. Tidd, D M. (1991) Synthetic oligonucleotides as therapeutic agents Br. J. Cancer. 63, 6-8.
41. Agrawal, S., Temsamani, J. and Tang, J. Y. (1992) Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci., 88, 7595-7599.
42. C'Brien, S. G., Kirkland, M. A. and Goldman, J. M. (1994) Antisense therapy for malianant disease. Eur J. Cancer, 30A, 1160-1164.
43. Loke, S. H., Stein, C., Zhang, X. H., Mon, K., Nakamshi, M , Subashinghe, C., Cohen, J. S. and Neckers, J. M. (1989) Characterization of oligonucleotide transport into living cells Proc. Natl. Acad. Sci., 86, 3474-3478.
44. Geselowitz, D. A. and Neckers, L. M (1992) Analysis of oligonucleotide binding, internalization, and intracellular trafficking utilizing a novel radiolabeled crosslinker Antisense Res Devel., 2, 17-25.
45. Boutorine, A. S., Boiziau, C., Le Doan, T., Toulmé, J. J. and Hélène, C. (1992) Effect of the terminal phosphate derivitization of β and α-oligodeoxynucleotides on their antisense activity in protein biosynthesis, stability and uptake by eukaryotic cells. Biochemie. 74, 485-489.
46. Citro, G , Perroti, D., Cucco, C , D'Agnano, I , Sacchi, A., Zupi, G. and Calabretta. B (1992) Inhibition of leukaemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad Sci. USA. 89, 7031-7035.
47. Lasic, D. D. and Papahadjopoulos, D. (1995) Liposomes revisited. Science, 267, 1275-1276.
48. Chatterjee, S., Johnson, P. R. and Wong, K. K. (1992) Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisens vector. Science, 258, 1485-1487.
49. BCR-ABL expression and inhibit the proliferation of BCR/ABL-contaming cell lines. Blood, 81, 502-509.
50. Miller, D. (1992) Human gene therapy comes of age. Nature, 357, 455-460.
51. Gutierrez, A. A., Lemoine, N. R. and Sikora, K. (1992) Gene therapy of cancer. Lancet, 339, 715-721.
52. Calabretta, B., Sims, R. B., Valtieri, M., Caracciolo, D., Szczylik, C., Venturelli, D., Ratajczak, M., Beran, M. and Gewirtz, A. M. (1991) Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides, an in vitro study relevant to bone marrow purging. Proc. Natl. Acad. Sci. USA, 88, 2351-2355.
53. Clark, S. S., McLaughlin, J., Crist, W. M., Champlin, R. and Writte. O. N (1987) Unique forms of the ab1 tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science, 235, 85-88.
54. Lugo, T. G., Pendergast, A. M , Muller, A. J. and Witte, O. N. (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247, 1079-1082.
55. Pendergast, A. M., Muller, A. J., Havlik, M. H., Maru, Y. and Witte, O. N. (1991) BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL-SH2 regulatory domain in a non-phospho-tyrosme-dependent manner. Cell. 66, 161-171.
56. McLaughlin, J., Chianese, E. and Witte, O. N. (1987) In vitro transformation of immature hematopoietic cells by the p210 bcr/abl oncogene product of the Philadelphia chromosome. Proc. Natl. Acad. Sci. USA, 84, 6558-6562.
57. Daley, G. Q., Van Etten, R. A. and Baltimore, D. (1990) Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science, 247, 824-830.
58. Daley, G. Q. and Ben-Neriah, Y. (1991) Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. Adv Cancer Res., 57, 151-184.
59. Voncken, J. W., Morris, C., Pattengale, P., Dennert, G., Kikly, C, Groffen, J. and Heisterkamp, N. (1992) Clonal development and karyotype evolution during leukemogenesis of BCR/ABL transgenic mice. Blood, 79, 1029-1036.
60. Szczylik, C., Skorski, T., Nicolaides, N. C., Manzella, L., Malaguarnera, L., Venturelli, D., Gewirtz, A. M. and Calabretta, B. (1991) Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligodeoxynucleotides. Science, 253, 562-565.
61. 1 leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J. Clin. Invest., 92, 194-202
62. De Fabritiis, P., Amadon, S., Calabretta, B and Mandelli, F. (1993) Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides. Bone marrow Transplantation. 12, 261-266.
63. Snyder, D. S., Wu, Y , Wang, J. L., Rossi, J. J., Swiderski, P., Kaplan, B. E. and Forman, S. J. (1993) Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood, 82, 600-605.
64. Skorski, T., Szczylik, C., Malaguamera, L. and Calabretta, B. (1991) Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides. Folia Hisiochemica el Cytobiologica, 29, 85-89.
65. Mahon, F. X., Belloc, F. and Reiffers, J. (1993) Antisense oligomers in chronic myeloid leukemia. Lancet, 341, 566.
66. Bishop, M. R., Joshi, S. S., Jackson, J. D., Wu, A. G., Sanger, W. G., Iversen, P. L., Bayever, E., Sharp, J. G., Zon, G. and Kessinger, A. (1994) Purging of peripheral blood progenitor cells with antisense oligonucleotide directed against BCR-ABL for chronic myelogenous leukemia. Blood, 84 (Suppl. 1, abstr. 2946), 740a.
67. Smetsers, F. C. M., Skorski, T., van de Locht, L. T. F., Wessels, H. M. C., Pennings, A H. M., Witte, T., Calabretta, B. and Mensink, E. J. B. M. (1994) Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia. 8, 129-140.
68. O'Brien, S. G., Kirkland, M. A., Melo, J. V., Rao, M H., Davidson, R. J., McDonald, C. and Goldman, J. M. (1994) Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines Leukemia, 8, 2156-2162.
69. Wagner, R. W. (1994) Gene inhibition using antisense oligodeoxynucleotides Nature, 372, 333-335.
70. Finlay, C. A , Hinds, P. W. and Levine, A J. (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell. 57, 1083-1093.
71. Eliyahu, D , Michlovitz, D., Eliyahu, S., Pinhasi-Kimhi, O. and Oren, M. (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA, 86, 8763-8767.
72. Diller, L., Kassel, J., Nelson, C. E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M., Baker, S. J., Vogelstein, B. and Friend, S. H. (1990) p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 10, 5772-5781.
73. Chen, P. L. Chen, Y., Bookstein, R. and Lee, W. H. (1990) Genetic mechanisms of tumor suppression by the human p53 gene. Science, 250, 1576-1580.
74. Bi, S., Lanza, F and Goldman, J. M. (1994) The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis. Cancer Res., 54, 582-586.
75. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991) p53 mutations in human cancers. Science, 253, 49-53.
76. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Clearly, K., Bingner, S. H., Davison, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C C and Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature, 342, 705-708.
77. Gaidano, G., Ballerini, P , Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., magrath, I. T., Knowles, D. M. and Dalla-Farera, R. (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88, 5413-5417.
78. Parada, L , Land, H., Weinberg, R., Wolf, D. and Rotter, W. (1984) Cooperation between gene encoding p53 rumour antigen and ras in cellular transformation. Nature, 312, 649-651.
79. Ahuja, H., Bar-Eli, M., Advani, S. H., Benchimol, S. and Cline, M. J. (1989) Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia Proc. Natl. Acad. Sci. USA, 86, 6783-6787.
80. Mashal, R., Shtalrid, M., Talpaz, M., Kantarjian, H., Smith, L., Beran, M., Cork, A., Trujillo, J., Gutterman, J. and Deisseroth, A. (1990) Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood, 75, 180-189
81. Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Hirai, H., Ishikawa, F. and Takaku, F. (1991) Mutations of the p53 gene in lymphoid leukemia. Blood, 77, 1153-1156.
82. Slingerland, J. M., Minden, M. D. and Benchimol, S. (1991) Mutation of the p53 gene in human acute myelogenous leukemia. Blood, 77, 1500-1507.
83. Bishop, M. R., Bayever, E., Iversen, P. L., Sharp, G., Spinolo, J., Zon, G., Smith, L J., Arneson, M., Ruddon, R., Armitage, J. and Kessinger, A. (1993) Phase I trial of systemic administration of OL(1)p53 oligonucleotide in refractory acute myelogenous leukemia and advanced myelodysplastic syndrome. Blood, 82 (Suppl. 1, abstr. 1757), 443a.
84. Coco, F. L., Gaidano, G., Louie, D. C., Offit, K., Chaganti, R. S. K and Dalla-Favera (1993) p53 mutations are associated with histologic transformation of follicular lymphoma. Blood, 82, 2289-2295.
85. Bayever, E., Haines, K. M. and Iversen, P. L. (1994) Selective cytotoxicity to human leukemic myeloblasts produced by otigodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk. Lymph. 12, 223-231.
86. Bayever, E. and Iversen, P. (1994) Oligonucleotides in the treatment of leukemia. Hematol. Oncol., 12, 9-14.
87. Spinolo, J., Iversen, P, Smith, L., Pirucello, S. J., Haines, K. M., Norton, S. E., Kay, H. D., Arneson, M. S., Cook, P., Zon, G. and Bayever, E. (1992) Antisense p53 oligodeoxynucleotide for systemic antileukaemic therapy Hum. Gene Ther. 3, 24A.
88. Barton, C. M. and Lemoine, N. R. (1995) Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer, 71, 429-437.
89. Mukhopadhyay, T. and Roth, J. (1993) A codon 248 p53 mutation retains tumor suppressor function as shown by enhancement of tumor growth by antisense p53. Cancer Res., 53, 4362-4366.
90. Anfossi, G., Gewirtz, A. M. and Calabretta, B. (1989) An oligomer complementary of c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc. Natl Acad. Sci. USA, 82, 3379-3383.
91. Gewirtz, A. M. and Calabretta, B. (1988) A c-myb antisense oligodeoxynucleotide inhibits normal human hematopoiesis in vitro. Science, 242, 1303-1306.
92. Ratajczak, M. Z., Kant, J. A., Luger, S. M., Hijiya, N., Zhang, J., Zon, G. and Gewirtz, A. M. (1992) In vivo treatment of human leukemia in a seid mouse model with c-myb antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA, 89, 11823-11827.
93. Rabbitts, T. H. (1994) Chromosomal translocations in human cancer. Nature, 372, 143-149.
94. Sentman, C. L. Shutter, J R., Hockenberry, D., Kanagawa, O. and Korsmeyer, S. J (1991) Bcl2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell, 67, 879-888.
95. Strasser, A., Harris A. W., and Cory, S. (1991) Bcl2 transgene inhibits T-cell death and perturbs thymic self-censorship. Cell, 67, 889-899.
96. Reed, J. C., Cuddy, M., Haldar, S., Croce, C., Nowell, P., Makover, D. and Bradley, K. (1990) BCL-2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with c-myc and inhibition by BCL-2 antisense Proc. Natl. Acad. Sci. USA, 87, 3660-3664.
97. Reed, J. C., Stein, C., Subasinghe, C., Haldar, S., Croce, C., Yum, S. and Cohen, J. (1990) Antisense-mediated inhibition of BCL-2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res., 50, 6565-6570.
98. Pocock, C., Al-Mahdi, N, Hall, P., Morgan, G. and Cotter, F. (1993) In vivo suppression of B-cell lymphoma with BCL-2 antisense oligonucleotides. Blood, 82 (Suppl. 1, abstr. 784), 200a.
99. McManaway, M. E., Neckers, L. M., Loke, S. L., Al-Nasser, A. A., Redner, R. L., Shiramizu, B. T., Goldschmidts, W. L., Huber, B. E., Bhatia, K. and Magrath, I. T (1990) Tumor-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet, 335, 808-811.
100. Azuma, E , Hiratake, S., Nishiguchi, Y., Tanaka, S. and Sakurai, M. (1993) Successful abrogation of P-glycoprotein expression of a munne multidrug-resistant leukemia cell line with anti-sense MDR oligomer. Blood 82 (Suppl. 1, abstr. 1014), 257a.
101. Schlaifer, D., Meyer, K., Muller, C., Attal, M., Smith, M. T., Tamaki, S., Weimels, J., Pris, J., Jaffrézou, J. P , Laurent, G. and Myers, C. E. (1994) Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine. Leukemia, 8, 289-291.